Skip to main content
NCBI home page
Gut logoLink to Gut
. 2001 Aug;49(2):288–294. doi: 10.1136/gut.49.2.288

Association of the tumour necrosis factor α −308 but not the interleukin 10 −627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis

S Mitchell 1, J Grove 1, A Spurkland 1, K Boberg 1, K Fleming 1, C Day 1, E Schrumpf 1, R Chapman 1, E the 1
PMCID: PMC1728404  PMID: 11454808

Abstract

BACKGROUND AND AIMS—Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown aetiology. Abnormalities in immune regulation and genetic associations suggest that PSC is an immune mediated disease. Several polymorphisms within the tumour necrosis factor α (TNF-α) and interleukin 10 (IL-10) promoter genes have been described which influence expression of these cytokines. This study examines the possible association between polymorphisms at the −308 and −627 positions in the TNF-α and IL-10 promoter genes, respectively, and susceptibility to PSC.
METHODS—TNF-α −308 genotypes were studied by polymerase chain reaction (PCR) in 160 PSC patients from Norway and the UK compared with 145 ethnically matched controls. IL-10 −627 genotypes were studied by PCR in 90 PSC patients compared with 84 ethnically matched controls.
RESULTS—A total of 16% of Norwegian PSC patients and 12% of British PSC patients were homozygous for the TNF2 allele compared with 3% and 6% of respective controls. The TNF2 allele was present in 60% of PSC patients versus 30% of controls (ORcombined data=3.2 (95% confidence intervals (CI) 1.8-4.5); pcorr=10−5). The association between the TNF2 allele and susceptibility to PSC was independent of the presence of concurrent inflammatory bowel disease (IBD) in the PSC patients; 61% of PSC patients without IBD had TNF2 compared with 30% of controls (ORcombined data=3.2 (95% CI 1.2-9.0); pcorr=0.006 ). There was no difference in the −627 IL-10 polymorphism distributions between patients and controls in either population. The increase in TNF2 allele in PSC patients only occurs in the presence of DRB1*0301 (DR3) and B8. In the combined population data, DRB1*0301 showed a stronger association with susceptibility to PSC than both the TNF2 and B8 alleles (ORcombined data=3.8, pcorr=10−6 v ORcombined data=3.2, pcorr=10−5 v ORcombined data =3.41, pcorr=10−4, respectively).
CONCLUSIONS—This study identified a significant association between possession of the TNF2 allele, a G→A substitution at position −308 in the TNF-α promoter, and susceptibility to PSC. This association was secondary to the association of PSC with the A1-B8-DRB1*0301-DQA1*0501-DQB1*0201 haplotype. No association was found between the IL-10 −627 promoter polymorphism and PSC.


Keywords: primary sclerosing cholangitis; tumour necrosis factor; interleukin 10; genetic polymorphism

Full Text

The Full Text of this article is available as a PDF (156.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernal W., Moloney M., Underhill J., Donaldson P. T. Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis. J Hepatol. 1999 Feb;30(2):237–241. doi: 10.1016/s0168-8278(99)80068-3. [DOI] [PubMed] [Google Scholar]
  2. Borish L., Aarons A., Rumbyrt J., Cvietusa P., Negri J., Wenzel S. Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol. 1996 Jun;97(6):1288–1296. doi: 10.1016/s0091-6749(96)70197-5. [DOI] [PubMed] [Google Scholar]
  3. Bouma G., Crusius J. B., García-González M. A., Meijer B. U., Hellemans H. P., Hakvoort R. J., Schreuder G. M., Kostense P. J., Meuwissen S. G., Peña A. S. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol. 1999 Feb;115(2):294–300. doi: 10.1046/j.1365-2249.1999.00797.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Braun N., Michel U., Ernst B. P., Metzner R., Bitsch A., Weber F., Rieckmann P. Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production. Neurosci Lett. 1996 Sep 6;215(2):75–78. [PubMed] [Google Scholar]
  5. Brinkman B. M., Zuijdeest D., Kaijzel E. L., Breedveld F. C., Verweij C. L. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm. 1995;46(1):32–41. [PubMed] [Google Scholar]
  6. Chapman R. W., Arborgh B. A., Rhodes J. M., Summerfield J. A., Dick R., Scheuer P. J., Sherlock S. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut. 1980 Oct;21(10):870–877. doi: 10.1136/gut.21.10.870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Danis V. A., Millington M., Hyland V., Lawford R., Huang Q., Grennan D. Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers. 1995 Mar;12(2):127–133. doi: 10.1155/1994/756247. [DOI] [PubMed] [Google Scholar]
  8. Farrant J. M., Doherty D. G., Donaldson P. T., Vaughan R. W., Hayllar K. M., Welsh K. I., Eddleston A. L., Williams R. Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology. 1992 Aug;16(2):390–395. doi: 10.1002/hep.1840160217. [DOI] [PubMed] [Google Scholar]
  9. Fowell D., Mason D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential. J Exp Med. 1993 Mar 1;177(3):627–636. doi: 10.1084/jem.177.3.627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gordon M. A., Oppenheim E., Camp N. J., di Giovine F. S., Duff G. W., Gleeson D. Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region. J Hepatol. 1999 Aug;31(2):242–247. doi: 10.1016/s0168-8278(99)80220-7. [DOI] [PubMed] [Google Scholar]
  11. Grove J., Daly A. K., Bassendine M. F., Gilvarry E., Day C. P. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut. 2000 Apr;46(4):540–545. doi: 10.1136/gut.46.4.540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Heresbach D., Ababou A., Bourienne A., Alizadeh M., Quelvennec E., Pagenault M., Dabadie A., Berre N. H., Campion J. P., Launois B. Etude du polymorphisme des microsatellites et des gènes du tumor necrosis factor (TNF) au cours des maladies inflammatoires chroniques de l'intestin. Gastroenterol Clin Biol. 1997;21(8-9):555–561. [PubMed] [Google Scholar]
  13. Hobbs K., Negri J., Klinnert M., Rosenwasser L. J., Borish L. Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. Am J Respir Crit Care Med. 1998 Dec;158(6):1958–1962. doi: 10.1164/ajrccm.158.6.9804011. [DOI] [PubMed] [Google Scholar]
  14. Jones D. E., Watt F. E., Grove J., Newton J. L., Daly A. K., Gregory W. L., Day C. P., James O. F., Bassendine M. F. Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. J Hepatol. 1999 Feb;30(2):232–236. doi: 10.1016/s0168-8278(99)80067-1. [DOI] [PubMed] [Google Scholar]
  15. Kroeger K. M., Carville K. S., Abraham L. J. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997 Apr;34(5):391–399. doi: 10.1016/s0161-5890(97)00052-7. [DOI] [PubMed] [Google Scholar]
  16. Lazarus M., Hajeer A. H., Turner D., Sinnott P., Worthington J., Ollier W. E., Hutchinson I. V. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol. 1997 Dec;24(12):2314–2317. [PubMed] [Google Scholar]
  17. Liblau R. S., Singer S. M., McDevitt H. O. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today. 1995 Jan;16(1):34–38. doi: 10.1016/0167-5699(95)80068-9. [DOI] [PubMed] [Google Scholar]
  18. Liblau R. S., Singer S. M., McDevitt H. O. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today. 1995 Jan;16(1):34–38. doi: 10.1016/0167-5699(95)80068-9. [DOI] [PubMed] [Google Scholar]
  19. Louis E., Satsangi J., Roussomoustakaki M., Parkes M., Fanning G., Welsh K., Jewell D. Cytokine gene polymorphisms in inflammatory bowel disease. Gut. 1996 Nov;39(5):705–710. doi: 10.1136/gut.39.5.705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Louis H., Van Laethem J. L., Wu W., Quertinmont E., Degraef C., Van den Berg K., Demols A., Goldman M., Le Moine O., Geerts A. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology. 1998 Dec;28(6):1607–1615. doi: 10.1002/hep.510280621. [DOI] [PubMed] [Google Scholar]
  21. McGuire W., Hill A. V., Allsopp C. E., Greenwood B. M., Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature. 1994 Oct 6;371(6497):508–510. doi: 10.1038/371508a0. [DOI] [PubMed] [Google Scholar]
  22. McManus R., Wilson A. G., Mansfield J., Weir D. G., Duff G. W., Kelleher D. TNF2, a polymorphism of the tumour necrosis-alpha gene promoter, is a component of the celiac disease major histocompatibility complex haplotype. Eur J Immunol. 1996 Sep;26(9):2113–2118. doi: 10.1002/eji.1830260923. [DOI] [PubMed] [Google Scholar]
  23. Mehal W. Z., Lo Y. M., Wordsworth B. P., Neuberger J. M., Hubscher S. C., Fleming K. A., Chapman R. W. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. Gastroenterology. 1994 Jan;106(1):160–167. doi: 10.1016/s0016-5085(94)95085-7. [DOI] [PubMed] [Google Scholar]
  24. Olerup O., Olsson R., Hultcrantz R., Broome U. HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology. 1995 Mar;108(3):870–878. doi: 10.1016/0016-5085(95)90463-8. [DOI] [PubMed] [Google Scholar]
  25. Park Y. B., Lee S. K., Kim D. S., Lee J., Lee C. H., Song C. H. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 1998 May-Jun;16(3):283–288. [PubMed] [Google Scholar]
  26. Spurkland A., Saarinen S., Boberg K. M., Mitchell S., Broome U., Caballeria L., Ciusani E., Chapman R., Ercilla G., Fausa O. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens. 1999 May;53(5):459–469. doi: 10.1034/j.1399-0039.1999.530502.x. [DOI] [PubMed] [Google Scholar]
  27. Svejgaard A., Ryder L. P. HLA and disease associations: detecting the strongest association. Tissue Antigens. 1994 Jan;43(1):18–27. doi: 10.1111/j.1399-0039.1994.tb02291.x. [DOI] [PubMed] [Google Scholar]
  28. Thompson K., Maltby J., Fallowfield J., McAulay M., Millward-Sadler H., Sheron N. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology. 1998 Dec;28(6):1597–1606. doi: 10.1002/hep.510280620. [DOI] [PubMed] [Google Scholar]
  29. Turner D. M., Grant S. C., Lamb W. R., Brenchley P. E., Dyer P. A., Sinnott P. J., Hutchinson I. V. A genetic marker of high TNF-alpha production in heart transplant recipients. Transplantation. 1995 Nov 27;60(10):1113–1117. doi: 10.1097/00007890-199511270-00010. [DOI] [PubMed] [Google Scholar]
  30. Turner D. M., Williams D. M., Sankaran D., Lazarus M., Sinnott P. J., Hutchinson I. V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997 Feb;24(1):1–8. doi: 10.1111/j.1365-2370.1997.tb00001.x. [DOI] [PubMed] [Google Scholar]
  31. Verjans G. M., Brinkman B. M., Van Doornik C. E., Kijlstra A., Verweij C. L. Polymorphism of tumour necrosis factor-alpha (TNF-alpha) at position -308 in relation to ankylosing spondylitis. Clin Exp Immunol. 1994 Jul;97(1):45–47. doi: 10.1111/j.1365-2249.1994.tb06577.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Wang S. C., Ohata M., Schrum L., Rippe R. A., Tsukamoto H. Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J Biol Chem. 1998 Jan 2;273(1):302–308. doi: 10.1074/jbc.273.1.302. [DOI] [PubMed] [Google Scholar]
  33. Wilson A. G., Gordon C., di Giovine F. S., de Vries N., van de Putte L. B., Emery P., Duff G. W. A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur J Immunol. 1994 Jan;24(1):191–195. doi: 10.1002/eji.1830240130. [DOI] [PubMed] [Google Scholar]
  34. Wilson A. G., Symons J. A., McDowell T. L., McDevitt H. O., Duff G. W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3195–3199. doi: 10.1073/pnas.94.7.3195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wilson A. G., de Vries N., Pociot F., di Giovine F. S., van der Putte L. B., Duff G. W. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med. 1993 Feb 1;177(2):557–560. doi: 10.1084/jem.177.2.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Wilson A. G., di Giovine F. S., Duff G. W. Genetics of tumour necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases. J Inflamm. 1995;45(1):1–12. [PubMed] [Google Scholar]
  37. Zappala F., Grove J., Watt F. E., Daly A. K., Day C. P., Bassendine M. F., Jones D. E. No evidence for involvement of the interleukin-10 -592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis. J Hepatol. 1998 May;28(5):820–823. doi: 10.1016/s0168-8278(98)80232-8. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES